HCA Health Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? HCA Health Inc trades at $443.69 (market cap $95.08B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.27 (market cap $2.28B). The key difference: HCA Health Inc is far larger — about 41.7× SELLAS Life Sciences Group Inc. Common Stock's market cap, and HCA Health Inc pays a 0.71% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| HCA | SLS | |
|---|---|---|
Market Cap | $95.08B | $2.28B |
Volume | 998,787 | 3,128,960 |
Sector | Health | Health |
52-Week High | $545.13 | $15.46 |
52-Week Low | $361.32 | $1.39 |
Typical Hold Time | 76 Days | — |
Enterprise Value | $145.62B | $2.15B |
Dividend Yield | 0.71% | — |
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $445.01, up 2.96% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.6B in 2025, with net income of $6.78B, and the stock trades at a P/E of 14.73. Analyst consensus is a Buy with a $461.12 price target, though ongoing legal investigations pose a headwind.
The outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and high debt levels. Upside potential exists if earnings growth continues, but investors should monitor legal developments and interest rate impacts on the leveraged balance sheet.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →